Seeking Alpha
 

Sinovac Biotech, Ltd. (SVA)

- NASDAQ
  • Nov. 14, 2014, 4:55 PM
    • Sinovac Biotech (NASDAQ:SVA): Q3 EPS of $0 beats by $0.01.
    • Revenue of $17.1M (-22.6% Y/Y) misses by $3.45M.
    • Shares -2.8% AH.
    • Press Release
    | Comment!
  • Aug. 14, 2014, 5:47 PM
    • Sinovac Biotech (NASDAQ:SVA): Q2 EPS of -$0.04 misses by $0.04.
    • Revenue of $12.1M (-30.9% Y/Y) misses by $5.1M.
    • Press Release
    | Comment!
  • Aug. 14, 2014, 5:03 PM
    • Sinovac Biotech Ltd. (SVA -0.5%) Q2 results: Revenues: $12.1M (-30.9%); Operating Expenses: $12.0M (+5.1%); Operating Loss: ($3.0M) (-257.9%); Net Loss: ($2.6M) (-211.9%); Loss Per Share: ($0.04) (-300.0%); Quick Assets: $89.6M (-16.4%); Cash Burn: ($5.6M) (-70.3%).
    • No financial guidance given.
    | Comment!
  • Aug. 14, 2014, 1:05 PM
    • Sinovac Biotech (NASDAQ:SVA): Q2 EPS of -$0.04
    • Revenue of $12.1M (-30.7% Y/Y)
    • Press Release
    | Comment!
  • May. 21, 2014, 6:05 PM
    • Sinovac Biotech (SVA): Q1 EPS of $0.00 beats by $0.03.
    • Revenue of $13.5M (+34.8% Y/Y) misses by $0.7M.
    • Press Release
    | Comment!
  • Mar. 19, 2014, 6:19 PM
    • Sinovac Biotech, Ltd. (SVA): Q4 EPS of $0.10.
    • Revenue of $22.94M (+17.1% Y/Y)
    • Press Release
    | 1 Comment
  • Nov. 13, 2013, 6:20 AM
    • Sinovac Biotech (SVA): Q3 EPS of $0.04.
    • Revenue of $22.1M (+54.5% Y/Y). (PR)
    | 1 Comment
  • Aug. 15, 2013, 1:59 PM
    • Sinovac Biotech (SVA -0.5%) takes a breather today after yesterdays big jump on a solid Q2.
    • Aegis Capital upped the shares from Hold to Buy earlier on the the back of the strong report with a $7 price target.
    • In the report, Aegis Capital notes that revenue easily beat its projections, mainly due to higher sales of the its hepatitis vaccines.
    • The firm also was encouraged by management's annnouncement that the NDA review of the EV71 vaccine targeting hand, foot, and mouth disease is moving into the technological review process stage at the Center for Drug Evaluation of the SFDA (the Chinese equivalent of the U.S. FDA).
    | Comment!
  • Aug. 14, 2013, 1:08 PM
    • Sinovac Biotech (SVA +8.2%) pops after its Q2 easily beat estimates this morning.
    • Sales increased by 86.4% to $17.5M from $9.4M.
    • Gross profit increased by 70.1% to $13.6M from $8.0M.
    • Net income was $1.3M, compared to net loss of $1.6M in the prior year.
    • Cash and cash equivalents totaled $92M, compared to $91.2M as of December 31, 2012.
    | Comment!
  • Aug. 14, 2013, 5:40 AM
    • Sinovac Biotech (SVA): Q2 EPS of $0.02 beats by $0.08.
    • Revenue of $17.5M (+86.4% Y/Y) beats by $5.88M. (PR)
    | Comment!
  • May. 28, 2013, 7:17 AM
    Sinovac Biotech (SVA): Q1 EPS of -$0.04 beats by $0.06. Revenue of $10.1M misses by $0.19M. (PR)
    | Comment!
  • Apr. 18, 2013, 8:26 AM
    Sinovac Biotech (SVA): FQ4 EPS of -$0.10 misses by $0.10. Revenue of $19M beats by $14.2M. (PR)
    | Comment!
  • Nov. 15, 2012, 6:31 AM
    Sinovac Biotech (SVA): Q3 EPS of -$0.06 misses by $0.03. Revenue of $14.3M (-7% Y/Y) beats by $2M. (PR)
    | Comment!
Visit Seeking Alpha's
SVA vs. ETF Alternatives
Company Description
Sinovac Biotech Ltd is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases.
Sector: Healthcare
Industry: Biotechnology
Country: China